If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.70    -0.27 (-13.71%)
Bid:
1.70
Ask:
2.00
Spread: 0.30 (17.647%)
Market Cap: £5.96m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director Dealing

31 Jul 2008 16:13

For Immediate Release 31 July 2008

PROTEOME SCIENCES plc

("Proteome Sciences" or the "Company")

PRESS RELEASE

DIRECTORS' SHAREHOLDINGS

Proteome Sciences announces that on 31 July 2008 it granted a conditional award of 1,882,500 Ordinary Shares of 1p each in the Company ("Ordinary Shares") to C.D.J. Pearce, Chief Executive and of 1,170,000 Ordinary Shares of 1p each to J.L. Malthouse, Finance Director, under its Long-Term Incentive Plan ("LTIP") based on a closing mid-market price on 30 July 2008 of 20p per Ordinary Share.

In accordance with the rules of the LTIP, the Ordinary Shares awarded will vest 3 years after the date of grant subject to the Company achieving a target total shareholder return (TSR) over a three-year performance period relative to the AIM Healthcare Index at the start of that period. TSR is the aggregate of share price growth and the value of dividend payments during the performance period. No shares will be released unless the Company's TSR performance exceeds that of the index, in which case 30% of the award will vest with full vesting only if the Company's TSR performance exceeds that of the Index by 10%, with a pro-rata award between 30% and 100% for each percentage point of out-performance up to 10%.

The Remuneration Committee of the Board of Directors believes that today's award under the LTIP aligns the interests of shareholders with those of the executive by making the award dependent on the success of management in delivering superior returns to shareholders.

C.D.J. Pearce currently holds 6,538,075 shares in the Company, and has a previous conditional award under the LTIP of up to 504,523 shares.

J.L. Malthouse currently holds 625,000 shares in the Company, and has a previous conditional award under the LTIP of up to 470,352 shares.

Ends

Proteome Sciences plc

Christopher Pearce James Malthouse

Chief Executive Officer Finance Director

christopher.pearce@proteomics.com james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Nominated Adviser

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes SpĴng Tel: +44 (0)20 7426 9000

vendor
Date   Source Headline
30th Jun 20104:27 pmRNSResult of AGM,Loan Conversion,Total Voting Rights
28th Jun 20105:59 pmRNSCOMPLETION OF PLACING AND OVERSUBSCRIBED OPEN OFFE
18th Jun 20107:00 amRNSUpdate on warranty claim
17th Jun 20109:00 amRNSReport and Accounts
11th Jun 20107:00 amRNSPublication of Circular
8th Jun 201011:21 amRNSHolding(s) in Company
7th Jun 20104:40 pmRNSSecond Price Monitoring Extn
7th Jun 20104:35 pmRNSPrice Monitoring Extension
7th Jun 20104:22 pmRNSPreliminary Results
7th Jun 20104:17 pmRNSPlacing, Open Offer & Loan Conversion
2nd Jun 20107:00 amRNSReimbursement of lung cancer test in USA
26th Apr 201011:55 amRNSBlocklisting Interim Review
9th Apr 20107:00 amRNSLicense Agreement
11th Feb 20108:18 amRNSAlliance with Parexel
9th Feb 20107:00 amRNSChange of Adviser
1st Feb 20102:01 pmRNSHolding(s) in Company
23rd Dec 20093:55 pmRNSDirectorate Change
16th Nov 20091:39 pmRNSHolding(s) in Company
28th Oct 20097:00 amRNSRe Contract
26th Oct 20097:00 amRNSBlock Admission
23rd Oct 20094:40 pmRNSSecond Price Monitoring Extn
23rd Oct 20094:35 pmRNSPrice Monitoring Extension
30th Sep 20097:00 amRNSHalf Yearly Report
25th Sep 20094:40 pmRNSSecond Price Monitoring Extn
25th Sep 20094:35 pmRNSPrice Monitoring Extension
10th Sep 20094:40 pmRNSSecond Price Monitoring Extn
10th Sep 20094:35 pmRNSPrice Monitoring Extension
9th Sep 20094:40 pmRNSSecond Price Monitoring Extn
9th Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:40 pmRNSSecond Price Monitoring Extn
28th Aug 20094:35 pmRNSPrice Monitoring Extension
16th Jul 20093:39 pmRNSHolding(s) in Company
14th Jul 200910:26 amRNSResult of AGM
6th Jul 20097:00 amRNSLicensing Agreement
30th Jun 20094:40 pmRNSSecond Price Monitoring Extn
30th Jun 20094:35 pmRNSPrice Monitoring Extension
22nd Jun 20098:00 amRNSPosting of Report & Accounts
18th Jun 20097:00 amRNSPreliminary Results
27th May 20097:00 amRNSLicense Agreement in Brain Damage
5th May 20092:40 pmRNSHolding(s) in Company
28th Apr 20092:20 pmRNSBlocklisting Interim Review
30th Mar 20097:00 amRNSChange of Adviser
23rd Mar 200910:30 amRNSHolding(s) in Company
18th Mar 20094:55 pmRNSHolding(s) in Company
9th Mar 20097:00 amPRNISO 9001: 2008 Certification
26th Feb 200911:09 amPRNCorrection : Holding(s) in Company
26th Feb 20099:00 amPRNHolding(s) in Company
15th Jan 20094:41 pmRNSSecond Price Monitoring Extn
15th Jan 20094:35 pmRNSPrice Monitoring Extension
6th Jan 20099:57 amPRNTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.